Weekly Analysts’ Ratings Updates for CRISPR Therapeutics (CRSP)

CRISPR Therapeutics (NASDAQ: CRSP) recently received a number of ratings updates from brokerages and research firms:

• 6/13/2026 – CRISPR Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/12/2026 – CRISPR Therapeutics was given a new $80.00 price target by UBS Group AG.
• 6/11/2026 – CRISPR Therapeutics was given a new $60.00 price target by Morgan Stanley. They now have an “equal weight” rating on the stock.
• 5/27/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/13/2026 – CRISPR Therapeutics had its price target raised by Sanford C. Bernstein from $50.00 to $56.00. They now have a “market perform” rating on the stock.
• 5/11/2026 – CRISPR Therapeutics had its “outperform” rating reaffirmed by Evercore Inc. They now have a $76.00 price target on the stock.
• 5/9/2026 – CRISPR Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/6/2026 – CRISPR Therapeutics had its price target raised by Citigroup Inc. from $80.00 to $82.00. They now have a “buy” rating on the stock.
• 4/20/2026 – CRISPR Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In related news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the transaction, the insider directly owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel James R. Kasinger sold 3,182 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $148,853.96. Following the transaction, the general counsel directly owned 94,308 shares in the company, valued at $4,411,728.24. This trade represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 16,988 shares of company stock valued at $828,167. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.